Alterations of Microstructure and Sodium Homeostasis in Fast Amyotrophic Lateral Sclerosis Progressors: A Brain DTI and Sodium MRI Study

References

1. 1.↵
   1. Chiò A,
   2. Moglia C,
   3. Canosa A, et al

   . Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology 2019;93:e984–94 doi:10.1212/WNL.0000000000008063 pmid:31409738

   Abstract/FREE Full Text
2. 2.↵
   1. Chiò A,
   2. Logroscino G,
   3. Traynor BJ, et al

   . Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 2013;41:118–30 doi:10.1159/000351153 pmid:23860588

   CrossRefPubMed
3. 3.↵
   1. Chiò A,
   2. Calvo A,
   3. Moglia C, et al

   ; PARALS Study Group. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 2011;82:740–46 doi:10.1136/jnnp.2010.235952 pmid:21402743

   Abstract/FREE Full Text
4. 4.↵
   1. Volk AE,
   2. Weishaupt JH,
   3. Andersen PM, et al

   . Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis. Med Genet 2018;30:252–58 doi:10.1007/s11825-018-0185-3 pmid:30220791

   CrossRefPubMed
5. 5.↵
   1. Marin B,
   2. Boumédiene F,
   3. Logroscino G, et al

   . Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol 2017;46:57–74 doi:10.1093/ije/dyw061 pmid:27185810

   CrossRefPubMed
6. 6.↵
   1. Pupillo E,
   2. Messina P,
   3. Logroscino G, et al

   ; SLALOM Group. Long-term survival in amyotrophic lateral sclerosis: a population-based study. Ann Neurol 2014;75:287–97 doi:10.1002/ana.24096 pmid:24382602

   CrossRefPubMed
7. 7.↵
   1. Kimura F,
   2. Fujimura C,
   3. Ishida S, et al

   . Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 2006;66:265–67 doi:10.1212/01.wnl.0000194316.91908.8a pmid:16434671

   Abstract/FREE Full Text
8. 8.↵
   1. Kollewe K,
   2. Mauss U,
   3. Krampfl K, et al

   . ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci 2008;275:69–73 doi:10.1016/j.jns.2008.07.016 pmid:18721928

   CrossRefPubMed
9. 9.↵
   1. Daghlas SA,
   2. Govindarajan R

   ; Pooled Resource Open-Access ALS Clinical Trials Consortium. Relative effects of forced vital capacity and ALSFRS-R on survival in ALS. Muscle Nerve 2021;64:346–51 doi:10.1002/mus.27344 pmid:34076262

   CrossRefPubMed
10. 10.↵
    1. Filippini N,
    2. Douaud G,
    3. Mackay CE, et al

    . Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology 2010;75:1645–52 doi:10.1212/WNL.0b013e3181fb84d1 pmid:21041787

    Abstract/FREE Full Text
11. 11.↵
    1. Winhammar JM,
    2. Rowe DB,
    3. Henderson RD, et al

    . Assessment of disease progression in motor neuron disease. Lancet Neurol 2005;4:229–38 doi:10.1016/S1474-4422(05)70042-9 pmid:15778102

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Gupta A,
    2. Nguyen TB,
    3. Chakraborty S, et al

    . Accuracy of conventional MRI in ALS. Can J Neurol Sci 2014;41:53–57 doi:10.1017/s0317167100016267 pmid:24384338

    CrossRefPubMed
13. 13.↵
    1. Jin J,
    2. Hu F,
    3. Zhang Q, et al

    . Hyperintensity of the corticospinal tract on FLAIR: a simple and sensitive objective upper motor neuron degeneration marker in clinically verified amyotrophic lateral sclerosis. J Neurol Sci 2016;367:177–83 doi:10.1016/j.jns.2016.06.005 pmid:27423585

    CrossRefPubMed
14. 14.↵
    1. Kassubek J,
    2. Müller HP

    . Advanced neuroimaging approaches in amyotrophic lateral sclerosis: refining the clinical diagnosis. Expert Rev Neurother 2020;20:237–49 doi:10.1080/14737175.2020.1715798 pmid:31937156

    CrossRefPubMed
15. 15.↵
    1. Basaia S,
    2. Filippi M,
    3. Spinelli EG, et al

    . White matter microstructure breakdown in the motor neuron disease spectrum: recent advances using diffusion magnetic resonance imaging. Front Neurol 2019;10:193 doi:10.3389/fneur.2019.00193 pmid:30891004

    CrossRefPubMed
16. 16.↵
    1. Steinbach R,
    2. Gaur N,
    3. Roediger A, et al

    . Disease aggressiveness signatures of amyotrophic lateral sclerosis in white matter tracts revealed by the D50 disease progression model. Hum Brain Mapp 2021;42:737–52 doi:10.1002/hbm.25258 pmid:33103324

    CrossRefPubMed
17. 17.↵
    1. Müller HP,
    2. Agosta F,
    3. Riva N, et al

    . Fast progressive lower motor neuron disease is an ALS variant: a two-centre tract of interest-based MRI data analysis. Neuroimage Clin 2018;17:145–52 doi:10.1016/j.nicl.2017.10.008 pmid:29071208

    CrossRefPubMed
18. 18.↵
    1. Brettschneider J,
    2. Del Tredici K,
    3. Toledo JB, et al

    . Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013;74:20–38 doi:10.1002/ana.23937 pmid:23686809

    CrossRefPubMed
19. 19.↵
    1. Grapperon AM,
    2. Ridley B,
    3. Verschueren A, et al

    . Quantitative brain sodium MRI depicts corticospinal impairment in amyotrophic lateral sclerosis. Radiology 2019;292:422–28 doi:10.1148/radiol.2019182276 pmid:31184559

    CrossRefPubMed
20. 20.↵
    1. Brooks BR,
    2. Miller RG,
    3. Swash M, et al

    ; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293–99 doi:10.1080/146608200300079536 pmid:11464847

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Cedarbaum JM,
    2. Stambler N,
    3. Malta E, et al

    . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function—BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13–21 doi:10.1016/S0022-510X(99)00210-5 pmid:10540002

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Labra J,
    2. Menon P,
    3. Byth K, et al

    . Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry 2016;87:628–32 doi:10.1136/jnnp-2015-310998 pmid:26152368

    Abstract/FREE Full Text
23. 23.↵
    1. Nagel AM,
    2. Laun FB,
    3. Weber MA, et al

    . Sodium MRI using a density-adapted 3D radial acquisition technique. Magn Reson Med 2009;62:1565–73 doi:10.1002/mrm.22157 pmid:19859915

    CrossRefPubMed
24. 24.↵
    1. Ridley B,
    2. Marchi A,
    3. Wirsich J, et al

    . Brain sodium MRI in human epilepsy: disturbances of ionic homeostasis reflect the organization of pathological regions. Neuroimage 2017;157:173–83 doi:10.1016/j.neuroimage.2017.06.011 pmid:28602596

    CrossRefPubMed
25. 25.↵
    1. Avants BB,
    2. Tustison NJ,
    3. Stauffer M, et al

    . The Insight ToolKit image registration framework. Front Neuroinform 2014;8:44 doi:10.3389/fninf.2014.00044 pmid:24817849

    CrossRefPubMed
26. 26.↵
    1. Manjón JV,
    2. Coupé P,
    3. Concha L, et al

    . Diffusion weighted image denoising using overcomplete local PCA. PLoS One 2013;8:e73021 doi:10.1371/journal.pone.0073021 pmid:24019889

    CrossRefPubMed
27. 27.↵
    1. Jenkinson M,
    2. Beckmann CF,
    3. Behrens TE, et al

    . FSL. Neuroimage 2012;62:782–90 doi:10.1016/j.neuroimage.2011.09.015 pmid:21979382

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Smith SM,
    2. Jenkinson M,
    3. Johansen-Berg H, et al

    . Tract-Based Spatial Statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006;31:1487–505 doi:10.1016/j.neuroimage.2006.02.024 pmid:16624579

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Bede P,
    2. Iyer PM,
    3. Schuster C, et al

    . The selective anatomical vulnerability of ALS: “disease-defining” and “disease-defying” brain regions. Amyotroph Lateral Scler Frontotemporal Degener 2016;17:561–70 doi:10.3109/21678421.2016.1173702 pmid:27087114

    CrossRefPubMed
30. 30.↵
    1. Steinbach R,
    2. Prell T,
    3. Gaur N, et al

    . Patterns of grey and white matter changes differ between bulbar and limb onset amyotrophic lateral sclerosis. Neuroimage Clin 2021;30:10267 doi:10.1016/j.nicl.2021.102674 pmid:33901988

    CrossRefPubMed
31. 31.↵
    1. Sach M,
    2. Winkler G,
    3. Glauche V, et al

    . Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. Brain 2004;127:340–50 doi:10.1093/brain/awh041 pmid:14607785

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Chapman MC,
    2. Jelsone-Swain L,
    3. Johnson TD, et al

    . Diffusion tensor MRI of the corpus callosum in amyotrophic lateral sclerosis. J Magn Reson Imaging 2014;39:641–47 doi:10.1002/jmri.24218 pmid:23843179

    CrossRefPubMed
33. 33.↵
    1. Zhang F,
    2. Chen G,
    3. He M, et al

    . Altered white matter microarchitecture in amyotrophic lateral sclerosis: a voxel-based meta-analysis of diffusion tensor imaging. Neuroimage Clin 2018;19:122–29 doi:10.1016/j.nicl.2018.04.005 pmid:30035009

    CrossRefPubMed
34. 34.↵
    1. Huhn K,
    2. Engelhorn T,
    3. Linker RA, et al

    . Potential of sodium MRI as a biomarker for neurodegeneration and neuroinflammation in multiple sclerosis. Front Neurol 2019;10:84 doi:10.3389/fneur.2019.00084 pmid:30804885

    CrossRefPubMed
35. 35.↵
    1. Schuster C,
    2. Hardiman O,
    3. Bede P

    . Survival prediction in amyotrophic lateral sclerosis based on MRI measures and clinical characteristics. BMC Neurol 2017;17:73 doi:10.1186/s12883-017-0854-x pmid:28412941

    CrossRefPubMed
36. 36.↵
    1. Spinelli EG,
    2. Riva N,
    3. Rancoita PMV, et al

    . Structural MRI outcomes and predictors of disease progression in amyotrophic lateral sclerosis. Neuroimage Clin 2020;27:102315 doi:10.1016/j.nicl.2020.102315 pmid:32593977

    CrossRefPubMed
37. 37.↵
    1. Sassani M,
    2. Alix JJ,
    3. McDermott CJ, et al

    . Magnetic resonance spectroscopy reveals mitochondrial dysfunction in amyotrophic lateral sclerosis. Brain 2020;143:3603–18 doi:10.1093/brain/awaa340 pmid:33439988

    CrossRefPubMed
38. 38.↵
    1. Vandoorne T,
    2. De Bock K,
    3. Van Den Bosch L

    . Energy metabolism in ALS: an underappreciated opportunity? Acta Neuropathol 2018;135:489–509 doi:10.1007/s00401-018-1835-x pmid:29549424

    CrossRefPubMed
39. 39.↵
    1. Stys PK,
    2. Waxman SG,
    3. Ransom BR

    . Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na(+)-Ca2+ exchanger. J Neurosci 1992;12:430–39 doi:10.1523/JNEUROSCI.12-02-00430.1992 pmid:1311030

    Abstract/FREE Full Text
40. 40.↵
    1. Kapoor R,
    2. Davies M,
    3. Blaker PA, et al

    . Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol 2003;53:174–80 doi:10.1002/ana.10443 pmid:12557283

    CrossRefPubMedWeb of Science
41. 41.↵
    1. Meier JM,
    2. van der Burgh HK,
    3. Nitert AD, et al

    . Connectome-based propagation model in amyotrophic lateral sclerosis. Ann Neurol 2020;87:725–38 doi:10.1002/ana.25706 pmid:32072667

    CrossRefPubMed